Semaglutide
Latest news, explainers and analysis on Semaglutide. Tracking 2 stories on Arth Vani.
Connected in the graph
Latest on Semaglutide
Dr. Reddy's Semaglutide Supply Faces Delay, No Recall Risk
Dr. Reddy's Laboratories has announced a delay in the supply of its Semaglutide, a key diabetes and weight-loss drug. The company clarified that this is a supply chain issue and not related to any quality concerns or a product recall.
Dr Reddy's Shares Drop 7% as Quality Issues Delay Weight-Loss Drug Launch
Shares of Dr Reddy’s Laboratories witnessed a sharp decline after the company paused commercial supplies of its semaglutide product. The delay stems from quality concerns regarding the active pharmaceutical ingredient (API) used in the drug.
Some listings may be sponsored and Arth Vani may earn a referral fee. All information is for educational purposes only — verify terms and suitability with the provider before acting. Not financial advice.